SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Synthetix is a decentralized perpetual futures protocol built on Ethereum Mainnet. Synthetix uses a hybrid design — off-chain order matching on a high-performance CLOB with on-chain settlement — to deliver low latency, deep liquidity, and MEV-resistant execution while keeping custody and finality on Ethereum. Traders get CEX-like performance with on-chain security and composability. The protocol’s liquidity is provided by the Synthetix Liquidity Provider (SLP) vault and backstopped by staked SNX collateral, which underwrites the issuance of the sUSD stablecoin and the solvency of the SLP vault.

Synthetix Network 

Synthetix Network is capturing significant attention due to its upcoming $1 million mainnet perpetuals trading competition and the launch of its V3 perps with multi-collateral support on Ethereum. The community is buzzing about the end of SNX token inflation and the start of buybacks, fueling bullish price speculation and increased trading volume.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is trending due to a mixed market reaction following recent financial updates, a significant share repurchase authorization, and conflicting analyst sentiment, sparking ongoing community debate over its competitive positioning against Salesforce in the life sciences CRM market and the long-term impact of its expanding AI strategy.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is surging after securing FDA approval for BYSANTI with unexpected New Chemical Entity status, providing robust patent protection until 2044, which the community hails as a "Gold Standard" and a significant re-rating event that could attract big pharma. Discussion is focused on this long-term revenue moat and the "mega blockbuster" potential of its Tradipitant for GLP-1 nausea.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending after the SEC dismissed its lawsuit and a significant partnership with AT&T emerged, solidifying its role in the DePIN sector. Community sentiment is highly polarized, with strong bullish conviction in its real-world utility and institutional interest contrasting with concerns over project management and token economics for miners.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending amidst excitement for its expanding "Intents" technology, enabling seamless cross-chain liquidity and AI agent interactions with networks like Solana and Starknet, alongside its participation in NVIDIA's Inception Program. The community actively discusses these technical advancements and tokenomics improvements as key to its long-term potential in the AI-driven crypto space.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

JFrog is trending due to a significant stock decline, with the community debating if the move is an overreaction to Anthropic's new AI code security capabilities, and questioning the broader impact on DevSecOps platforms. While some investors see a buying opportunity, others are taking profits or shorting, leading to calls for management to address the market's concerns.

KeyCorp is a bank holding company, which engages in the provision of financial services. It operates through the Consumer Bank and Commercial Bank segments. The Consumer Bank segment offers deposit and investment products, personal finance and financial wellness services, lending, mortgage and home equity, student loan refinancing, credit card, treasury services, and business advisory services. The Commercial Bank segment focuses on serving the needs of middle market clients in seven industry sectors, consumer, energy, healthcare, industrial, public sector, real estate, and technology. The company was founded on December 31, 1958 and is headquartered in Cleveland, OH.

Keycorp

KeyCorp is trending as First Citizens BancShares is reportedly exploring a potential acquisition to quickly surpass $250 billion in assets, driving community discussion around the possibility of a takeout and its implications for share repricing. This news comes amidst ongoing chatter about KeyCorp's mixed momentum indicators despite recent revenue growth and strategic restructuring efforts.

Builders FirstSource, Inc. engages in the supply and manufacture of building materials, manufactured components, and construction services to professional homebuilders, sub-contractors, remodelers, and consumers. Its products include factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The company was founded by Kevin P. O'Meara, Donald F. McAleenan and John D. Roach in March 1998 and is headquartered in Irving, TX.

Builders Firstsource Inc

Builders FirstSource is trending after its Q4 earnings missed estimates, triggering concerns about declining sales, margins, and increasing debt pressure. This financial uncertainty clashes with bullish sentiment fueled by recent insider buying, speculation of a potential acquisition, and a long-term belief in the housing sector's rebound and value.

Tronox Holdings Plc engages in the mining and inorganic chemical business. Its products include Titanium Dioxide Mineral Sands. The firm also mines and processes titanium ore, zircon and other minerals, and manufactures titanium dioxide pigments. The company was founded in 2006 and is headquartered in Stamford, CT.

Tronox Holdings plc - Ordinary Shares - Class A

Tronox Holdings is trending as it secures conditional support for up to $600 million in rare earth project financing from the U.S. and Australian export banks, fueling community excitement over its critical minerals strategy and a potential chemical sector rebound. Investors are actively discussing the growth prospects and potential for a short squeeze following a positive earnings outlook.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is gaining traction following the appointment of a new CEO after an extended search, alongside mixed reactions to recent Q4 results which noted a decline in same-store sales and moderated growth plans. The community is sharply divided, with some questioning the new leadership's experience and operational missteps, while a strong bullish contingent sees the beloved brand as significantly undervalued and poised for a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences (HURA) to Release Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of...

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR...

<ul class="summary-bullets"><li>Orphan drug status adds regulatory incentives and boosts visibility for IFx-2.0.</li><li>Early trial data showed the treatment was safe with signs of benefit.</li><li>The news reignited retail interest after recent analyst resets, pipeline updates, and a financing that extended the company’s development runway.</li></ul>Shares of TuHURA Biosciences drew intense retail chatter on Tuesday after the company said the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its melanoma therapy.<h2 class="st-heading-2">FDA Orphan Drug Designation For IFx-2.0</h2>TuHURA said the FDA’s Office of Orphan Products Development granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. The designation is based on data from a previously completed Phase 1 study, which showed IFx-2.0 was safe with no serious dose-limiting toxicities.The study also&nbsp;found that some patients whose cancers had stopped responding to prior immunotherapy later responded when treated with standard immune checkpoint inhibitors.Orphan Drug Designation provides seven years of market exclusivity upon approval, along with tax credits for certain research costs, access to FDA grants, better regulatory guidance, and a waiver of New Drug Application user fees.TuHURA said its near-term focus remains on completing enrollment in its Phase 3 trial of IFx-2.0 in combination with Keytruda for first-line treatment of advanced or metastatic Merkel cell carcinoma.<h2 class="st-heading-2">Portfolio Updates</h2>In December, TuHURA announced the release of contingent value rights tied to legacy Kintara Therapeutics assets after a REM-001 clinical trial in metastatic cutaneous breast cancer met its primary endpoint, demonstrating safety and signs of clinical efficacy. The milestone triggered the release of more than 1.5 million TuHURA shares to former Kintara stockholders under the CVR agreement.Additionally, the company highlighted early research and patient-related data supporting its experimental antibody, TBS-2025, which it said showed survival benefits, particularly when used alongside standard chemotherapy or other targeted treatments.TuHURA also said a recently completed financing, which raised $15.6 million in gross proceeds, is expected to fund key milestones across its three development programs, including IFx-2.0, TBS-2025, and earlier-stage immune-modulating platforms.Last month,&nbsp; H.C. Wainwright lowered its price target on TuHURA to $10 from $12 while maintaining a ‘Buy’ rating. The brokerage said at the time that upcoming value inflection points, combined with a recent decline in the stock, created what he described as an attractive entry point for investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TuHURA was ‘bullish’ amid a 7,300% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hura_ss_png_6d663076c8.webp" alt="hura ss.png" width="971" height="139"><figcaption>HURA sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user called the fall in stock price a “real loading zone.”<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643709473</stembedurl>Another trader suggested the company’s latest capital raise could wrap up much earlier than expected.<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643695662</stembedurl><a href="https://stocktwits.com/symbol/HURA">TuHURA’s stock</a> has declined 90% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TuHURA’s stock has declined 90% over the past 12 months. (Representative Image: Getty Images)

This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why

Hura Stock - The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

HURA Stock Sparks 7,000% Surge In Retail Chatter After FDA Orphan Drug Win For Melanoma Therapy

Equity

The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone TuHURA Biosciences Announces its...

TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday...

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences Provides Corporate Update Following Recent Financing TuHURA Biosciences Provides Corporate Update Following Recent Financing PR Newswire TAMPA, Fla., Dec. 11, 2025 Company's lead...

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering PR Newswire TAMPA, Fla., Dec. 9, 2025 TAMPA...

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and...

TuHURA Biosciences (NASDAQ:HURA) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Saturday...

This account has been verified as an official HURA representative.

Verified Account

Tu HURA IR

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

HURA
TuHURA Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HURA News

HURATuHURA Biosciences Inc.